Dr. Kathryn A. Bylow, MD

Dr. Bylow practices at Froedtert Hospital in Milwaukee, Wisconsin, part of Froedtert ThedaCare Health.

Dr. Bylow's NPI, 1437370095, was assigned on May 1, 2007. Dr. Bylow graduated from University of Wisconsin-Madison in 2000. Dr. Bylow's Wisconsin license number on file is 50273.

Dr. Bylow's primary practice is Froedtert Hospital, at 9200 W Wisconsin Ave, Milwaukee, WI 53226 in Milwaukee County. The practice phone is (414) 805-3000.

Dr. Bylow's primary practice is Froedtert Hospital in Milwaukee, Wisconsin, part of Froedtert ThedaCare Health. The medical group on file is Froedtert & the Medical College of Wisconsin Community Physicians. Dmand AI also links Dr. Bylow to 1 more home health agency, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bylow practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bylow's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bylow is board certified in geriatric medicine by the American Board of Internal Medicine. Dmand AI has Dr. Bylow's licenses on file in 2 states: Wisconsin and Illinois.

Dmand AI lists prostate cancer among the conditions Dr. Bylow treats.

CMS data shows 590 Medicare services from Dr. Bylow across 6 procedure codes in 2024, for 125 Medicare patients. Medicare paid $35,873 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 125 Medicare patients who saw Dr. Bylow in 2024. The largest group is 65 to 74, with 55 patients. 75% of them have cancer, and 74% have high blood pressure. Their average risk score is 2.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bylow's median patient age at 72, with 15% women.

In 2024, Dr. Bylow wrote 524 Medicare Part D claims for 88 patients. 69% of them were for generic drugs. CMS names the drug for 341 of them, across 11 drugs with 11 or more claims each, at $1,428,739 in total drug cost. In 2023, CMS named 230 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Bylow for performance year 2024, reported as part of a group. Dr. Bylow accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bylow as offering telehealth.

Dmand AI links 22 papers to Dr. Bylow, published from 2008 to 2025. 2013 was the busiest year, with 3. The most frequent topics are Prostatic Neoplasms, Androgen Antagonists and Accidental Falls. Dr. Bylow has published most often in Clin Genitourin Cancer. Dr. Bylow's most frequent co-authors are William Dale, MD, PhD, John D. Burfeind, MD and Ben George, MD.

Dmand AI links Dr. Bylow to 8 clinical trials, 4 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Ureteral Neoplasms and Kidney Neoplasms. National Cancer Institute (NCI) sponsors the most, 3. Open Payments lists research payments to Dr. Bylow that name 1 trial.

CMS Open Payments shows 8 general payments to Dr. Bylow from 5 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 74% of the total. Exelixis Inc. paid the most, $309. It also lists 2 research payments totaling $1,297 from 2016 to 2017, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Bylow, most recently CMS Stage 1 EHR in 2013.

Dr. Bylow graduated from University of Wisconsin-Madison in 2000. Dr. Bylow is a member of ASCO.

Dr. Bylow is in network with 16 carriers, including Aetna, United Healthcare and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.